Superpower peptides available for pre-order. Get first access.

Peptide science

How does methylene blue relate to peptides?

Methylene blue is a dye, not a peptide, and FDA-approved only for methemoglobinemia. See why it is grouped with peptides, its risks, and the evidence.

Quick answer

Methylene blue is a phenothiazine dye, not a peptide, and the FDA approves it only for acquired methemoglobinemia. Researchers group it with MOTS-c, humanin, Semax, and Selank for shared interest in cellular energy and cognition, not a shared mechanism. Most evidence is cell and animal work. A phase 3 trial of LMTM, a related compound, in 891 people with Alzheimer's disease missed its primary outcomes.

Published
April 18, 2026
Last updated
November 12, 2026

Key takeaways

  • Methylene blue, also called methylthioninium chloride, is a small synthetic phenothiazine dye1 rather than a peptide.
  • Methylene blue is FDA-approved only for acquired methemoglobinemia2, a blood disorder, so every cognitive, mitochondrial, or anti-aging use is off-label.
  • Researchers study methylene blue and peptides for some of the same goals, mainly cellular energy and cognition, through different mechanisms.
  • Most methylene blue research comes from cell and animal studies. A phase 3 trial of LMTM, a related compound, found no benefit on its primary outcomes in 891 people with Alzheimer's disease3.

What is methylene blue?

Methylene blue (MB; also designated as methylthioninium chloride) is a phenothiazine dye, not a peptide. Methylene blue is a small synthetic aromatic compound with the molecular formula C₁₆H₁₈ClN₃S1. Methylene blue is approved by the FDA under the brand name Provayblue (Provepharm) for one specific clinical indication2: acquired methemoglobinemia in adults and pediatric patients.

German chemist Heinrich Caro first prepared methylene blue in 18764 as a textile dye5, and the compound has been called the first fully synthetic drug used in medicine.

As of November 2026, methylene blue has no FDA approval for any cognitive, mitochondrial, nootropic, or anti-aging application. Methylene blue's off-label research centers on cellular energy and brain function, the same questions that draw researchers to several peptides.

Why methylene blue is grouped with peptides

Methylene blue gets grouped with peptides because researchers study both for similar goals, mainly mitochondrial energy production and cognition, through different chemical mechanisms. Those shared goals describe what researchers measure and offer no evidence about combining these compounds.

MOTS-c and humanin

The overlap between methylene blue, MOTS-c, and humanin is bioenergetic. All three have been studied for how cells make energy under stress.

In cell and rodent studies, methylene blue passes electrons from NADH to cytochrome c6, opening an alternative route through the mitochondria. Methylene blue's low and high doses can have opposite effects7 in animals.

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA8. In cell studies, MOTS-c regulates genes under metabolic stress9 through AMPK, an energy-sensing enzyme, instead of carrying electrons.

Humanin was the first mitochondrial-derived peptide identified10. In human retinal cells exposed to oxidative stress, humanin restored mitochondrial respiration11. Both peptides act as signaling molecules, while methylene blue moves electrons itself.

Semax and Selank

Semax and Selank share methylene blue's research interest in cognition but act on different brain systems.

Semax is a synthetic seven-amino-acid peptide. In rats, Semax raised brain levels of BDNF12, a protein that supports nerve cells. In rat frontal cortex, Selank changed the activity of genes tied to GABA13, the brain's main calming messenger.

For methylene blue, a small randomized trial found that one low oral dose increased brain responses during attention and memory tasks14 in healthy adults.

Off-label research interest

Much of the renewed research interest in methylene blue comes from its role in mitochondria. Researchers have reported protective effects in cell and animal models15 of stroke, Alzheimer's disease, and Parkinson's disease.

Researchers have also explored methylene blue as a potential Alzheimer's drug16 that may stop tau protein from clumping.

The main safety risks of methylene blue

Methylene blue carries serious prescription-drug risks in any use, and some rule the drug out for certain people.

With risks this serious, the strength of the off-label evidence matters.

What the research on methylene blue shows

Most evidence for methylene blue's off-label uses comes from cell and animal research. Human studies so far are small, mixed in their results, or low in certainty. A large Alzheimer's trial of LMTM, a related compound, found no benefit on its main outcomes.

Evidence typeWhat existsExampleStatus
PreclinicalCell and rodent studies of mitochondrial function and neuroprotectionIn human fibroblast cultures, methylene blue raised complex IV activity by 30%21 and delayed cell agingEarly-stage; effects not shown in people
Human imaging and memorySmall studies in healthy adults and adults with claustrophobiaLower brain blood flow and oxygen use22 in healthy volunteers, against the researchers' hypothesis; better contextual memory in 42 adults23 with claustrophobia, with a fear-reduction benefit only in low-fear participantsSmall and mixed
Confirmatory phase 3 (LMTM, related compound)Randomized trial in mild to moderate Alzheimer's disease, 15 monthsNo benefit on either primary outcome3 at either dosePrimary analysis negative
Septic and distributive shockMeta-analyses of small randomized trials6 trials, 302 adults with septic shock: possible lower short-term mortality, low certainty24; 6 trials, 265 patients with distributive shock: no significant mortality difference25Investigational, low certainty

Peptides studied beside methylene blue deserve the same evidence-first reading.

Where can I learn about peptides?

Methylene blue shows how easily a non-peptide drug ends up filed under peptides. Superpower’s peptide library is written and fact-checked by a team of health journalists and licensed clinicians. Each guide separates what a compound is from what research has tested.

Judging any compound by its evidence gets easier once the basics are clear. The science behind peptides covers what makes a molecule a peptide in the first place.

Important safety information

Methylene blue is approved by the FDA as Provayblue, an intravenous prescription drug, only for acquired methemoglobinemia in adults and children. Full prescribing and safety information for the approved product is available in its FDA-approved labeling.

Uses outside the approved indication, including those discussed on this page (cognitive enhancement, mitochondrial support, anti-aging applications, and combined use with peptides), are off-label. Off-label prescribing is permitted under the practice of medicine but has not been evaluated or endorsed by the FDA.

The peptides referenced on this page (MOTS-c, humanin, Semax, and Selank) are not FDA-approved for human use. Superpower is a technology platform; Superpower does not prescribe, sell, compound, or facilitate access to methylene blue, humanin, or Selank. This page is for educational purposes only and does not constitute medical advice.

BOXED WARNING (from the FDA-approved Provayblue label): Serotonin syndrome. Methylene blue may cause serious or fatal serotonin syndrome when used with serotonergic drugs and opioids. The label advises avoiding use alongside selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and opioids. Methylene blue is a potent reversible MAO-A inhibitor.

Contraindications on the label: severe hypersensitivity to methylene blue or any other thiazine dye, and glucose-6-phosphate dehydrogenase (G6PD) deficiency, because of the risk of hemolytic anemia. Methylene blue may cause fetal harm in pregnancy, and the label advises stopping breastfeeding during and for up to 8 days after a dose.

Warnings on the label: severe allergic reactions, including anaphylaxis; hemolytic anemia, which may appear 1 or more days after a dose; underestimated oxygen saturation readings on pulse oximetry; confusion, dizziness, and vision changes that affect driving and operating machinery; and blue discoloration of urine, other body fluids, and skin. Chemical-grade methylene blue sold as a dye or stain is not pharmaceutical grade and may contain heavy-metal contaminants, including lead and arsenic.

Most common side effects on the label (2% or more): headache, low potassium, diarrhea, low magnesium, muscle jerks (myoclonus), nausea, and seizure-like phenomena.

Long-term data limitations: No phase 2 or phase 3 randomized controlled trial has established efficacy for methylene blue in cognitive enhancement, mitochondrial support, or anti-aging applications in humans, and the phase 3 trial of LMTM, a related compound, in Alzheimer's disease missed its primary outcomes. None of the peptides discussed alongside methylene blue on this page (MOTS-c, humanin, Semax, and Selank) has completed FDA approval or published phase 3 efficacy data in the United States.

Compound references: Provayblue DailyMed label2; PubChem CID 6099 (methylene blue)1. For the peptides discussed in this article, see individual compound pages for specific regulatory status and evidence.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science